Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.

10 Nov 2015

$Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented$

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Takeda Pharmaceutical Company Limited today announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015.

6 Nov 2015

Differences in vitamin D status may account for disparities in breast cancer survival rates

The American Cancer Society just published a paper reporting that while breast cancer incidence rates for 2008-2012 were similar for black and white women, death rates were 42% higher for black women [DeSantis, 2015]. The factors suggested to explain the disparity in mortality rates included difference in stage at diagnosis, obesity, comorbidities, tumor characteristics, as well as access, adherence, and response to treatments.

5 Nov 2015

Janssen doses first patient in daratumumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that Janssen Biotech, Inc. has dosed the first patient in a clinical trial evaluating subcutaneous (SC) delivery of daratumumab with Halozyme's proprietary ENHANZE technology in multiple myeloma.

5 Nov 2015

Innovative immunotherapy clinical trial underway at The University of Kansas Cancer Center

A novel immunotherapy clinical trial underway now at The University of Kansas Cancer Center has enrolled the first patients in the world to receive what many doctors and researchers believe is the future of cancer treatment.

4 Nov 2015

Around 20% of ethnic school girls not vaccinated against HPV

Around 20 per cent of girls from ethnic minority backgrounds are not being vaccinated against the Human Papilloma Virus (HPV) because they feel they don't need to have it, according to a Cancer Research UK survey presented today at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool*.

2 Nov 2015

Researchers develop cancer-killing 'grenades’

Researchers have developed cancer drug-packed 'grenades' armed with heat sensitive triggers, allowing for treatment to be targeted directly at tumours, according to two studies due to be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.

31 Oct 2015

Resistance to CD19 CAR T-cell therapy can be caused by CD19 splicing alterations

Resistance to CD19 CAR T-cell therapy, a type of immunotherapy that yields long-lasting remissions in many patients with B-cell leukemia, can be caused by CD19 splicing alterations, leading to loss of certain parts of the CD19 protein that are recognized by the CAR T cells.

31 Oct 2015

Researchers discover key regulator that impacts survival of lymphoma patients

An important regulator that controls the ability of tumour cells to hide from the immune system in lymphoma patients, making them unlikely to respond to standard treatment, has been discovered by scientists at the University of Oxford.

31 Oct 2015

Specialized type of immunotherapy can boost survival from pancreatic cancer

A new study in mice by researchers at Fred Hutchinson Cancer Research Center has found that a specialized type of immunotherapy — even when used without chemotherapy or radiation — can boost survival from pancreatic cancer, a nearly almost-lethal disease, by more than 75 percent. The findings are so promising, human clinical trials are planned within the next year.

30 Oct 2015

New research shows that autophagy can operate in cell nucleus to guard against start of cancer

Autophagy, literally self-eating or the degradation of unwanted cellular bits and pieces by the cell itself, has been shown for the first time to also work in the cell nucleus. In addition, in this setting it plays a role in guarding against the start of cancer, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

29 Oct 2015

Targeting invasive cells could be a new strategy to treat metastatic cancer, say Stony Brook researchers

Most cancer drugs are designed to target dividing cells, but a new study by Stony Brook University researchers suggests that targeting invasive cells may be a new strategy to treat metastatic cancer.

27 Oct 2015

DNA study reveals basic principle of gene regulation

A study of where and how an enzyme cuts DNA may have inadvertently revealed a basic principle of gene regulation, say researchers in Boston Children's Hospital's Program in Cellular and Molecular Medicine (PCMM).

23 Oct 2015

CML arterial adverse events rate dependent on TKI choice

The risk of major arterial adverse events in chronic myeloid leukaemia patients may significantly differ between tyrosine kinase inhibitors, suggests a meta-analysis published in Leukemia & Lymphoma.

22 Oct 2015

‘Dismal prognosis’ of blast-phase CML patients highlighted

A team of Mexican researchers reports on the poor outcomes of a large series of Mexican patients with chronic myeloid leukaemia in blast phase.

22 Oct 2015

UAMS researchers report positive results from treating Metastatic Merkel-cell carcinoma with idelalisib drug

Identifying a patient's genetic mutation led University of Arkansas for Medical Sciences (UAMS) physician-researcher Ling Gao, M.D., Ph.D., to an existing drug that eliminated the patient's stage IV Merkel-cell carcinoma. Gao's findings, made in collaboration with two other UAMS researchers, were published today in The New England Journal of Medicine.

19 Oct 2015

Researchers explain how incurable type of blood cancer develops

Researchers in the West Midlands have made a breakthrough in explaining how an incurable type of blood cancer develops from an often symptomless prior blood disorder. The findings could lead to more effective treatments and ways to identify those most at risk of developing the cancer.

18 Oct 2015

Set of genes identified in human genome essential for survival, proliferation of human cell lines

Using two complementary analytical approaches, scientists at Whitehead Institute and Broad Institute of MIT and Harvard have for the first time identified the universe of genes in the human genome essential for the survival and proliferation of human cell lines or cultured human cells.

16 Oct 2015

Study suggests combination of MMF and CNIs can protect against rare lymphoma

16 Oct 2015

Researchers link organ transplant drug to rise in rare lymphoma

A study led by Johns Hopkins researchers has linked the immunosuppressive drug mycophenolate mofetil (MMF) to an increased risk of central nervous system (CNS) lymphoma in solid organ transplant patients. But the same study also found that another class of immunosuppressive drugs, called calcineurin inhibitors (CNIs), given alone or in combination with MMF, appears to protect transplant patients against this rare form of lymphoma.

15 Oct 2015

Lymphoma News and Research

Further Reading

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Differences in vitamin D status may account for disparities in breast cancer survival rates

Janssen doses first patient in daratumumab clinical trial using Halozyme's ENHANZE technology

Innovative immunotherapy clinical trial underway at The University of Kansas Cancer Center

Around 20% of ethnic school girls not vaccinated against HPV

Researchers develop cancer-killing 'grenades’

Resistance to CD19 CAR T-cell therapy can be caused by CD19 splicing alterations

Researchers discover key regulator that impacts survival of lymphoma patients

Specialized type of immunotherapy can boost survival from pancreatic cancer

New research shows that autophagy can operate in cell nucleus to guard against start of cancer

Targeting invasive cells could be a new strategy to treat metastatic cancer, say Stony Brook researchers

DNA study reveals basic principle of gene regulation

CML arterial adverse events rate dependent on TKI choice

‘Dismal prognosis’ of blast-phase CML patients highlighted

UAMS researchers report positive results from treating Metastatic Merkel-cell carcinoma with idelalisib drug

Researchers explain how incurable type of blood cancer develops

Set of genes identified in human genome essential for survival, proliferation of human cell lines

Study suggests combination of MMF and CNIs can protect against rare lymphoma

Researchers link organ transplant drug to rise in rare lymphoma

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News